Brentuximab vedotin (cAC10-vcMMAE) is an antibody-drug conjugate (ADC) comprising an anti-CD30 antibody and the cytotoxic agent Monomethyl auristatin E (MMAE). Brentuximab vedotin inhibits CD30-positive cells with an IC50 of 2.5 ng/mL. Brentuximab vedotin can be used for the research of relapsed and refractory Hodgkin lymphoma.
Purity:
99.0%
CAS Number:
[914088-09-8]
Target:
Drug-Linker Conjugates for ADC
* VAT and and shipping costs not included. Errors and price changes excepted